Entos Pharmaceuticals Inc.
$10,000,000.00 CAD
- Department
- National Research Council Canada
- Recipient country
- Canada
- Fiscal year
- 2022-2023
- Agreement period
- September 1, 2022 – March 31, 2024
- Reference
- nrc-cnrc:172-2022-2023-Q4-1000363
Published purpose
Entos has developed Covigenix VAX-001, a DNA Proteo-Lipid Vehicle (PLV) vaccine intended for the prevention of COVID-19 infection by SARS-CoV-2. In this project, Entos will advance the VAX-001-1c bivalent vaccine candidate through Phase 3 clinical trials to establish its safety and immunogenicity in healthy adults as a booster to approved vaccines.
In plain English AI-generated
Funding supports Entos Pharmaceuticals in advancing its COVID-19 bivalent vaccine candidate through Phase 3 clinical trials to assess safety and immunogenicity as a booster in healthy adults.
Category: Health Primarily funds activity in Canada
Based on the published description. See how AI categorization works — the linked official record is authoritative.
Community tags
Tags are applied by readers, not by this site. One tag per person per record.